Participated · Series A · Nov 2021

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing targeted radiopharmaceutical therapies (TRT) against tumor targets. The company is focused on building a pipeline of advanced TRT products aimed at treating solid tumors. It plans to use the Series A proceeds to expand its leadership team, build radiopharmaceutical infrastructure, and secure strategic collaborations. Ablaze has a partnership with RayzeBio that grants it exclusive development and commercial rights to a series of RayzeBio’s products in the greater China region. Founded in 2021 and led by co-founder, President and CEO Dr. Alex Qiao, Ablaze operates out of Shanghai, China and San Diego, CA. The company raised $75M in a Series A financing to advance its clinical and commercialization efforts.

Participated · Series A · Nov 2021

Fountain Therapeutics builds a pipeline of disease-modifying therapeutics for chronic degenerative diseases using a cell-based, AI-driven technology platform that leverages machine learning and computer vision alongside biology of aging. The platform enables precise mapping of cellular biologic age and extraction of cellular features to identify novel targets and disease biomarkers. Fountain has translated these insights into an unbiased drug discovery and development engine aimed at therapies that restore cellular resilience. The company announced a $15 million Series A-2 financing, bringing its total Series A funding to $26 million. Proceeds will support expansion of the leadership team, continued R&D activities, pre-clinical research, and further development of its platform and pipeline. The announcement was released from San Francisco. Fountain Therapeutics builds a pipeline of therapeutics intended to treat age-related diseases by reversing cellular age. The company uses a cell-based, AI-driven technology platform that extracts cellular features to provide insights into the aging process. Its leadership includes CEO John Dimos, Ph.D. Fountain plans to use recent funding to expand its senior leadership team and enhance its technology platform capabilities. The company intends to advance novel therapeutics identified by the platform through preclinical testing in animal models. As of the announced financing, Fountain has increased its Series A funding to a total of $11M.

Led · Series A · Aug 2021

Engrail Therapeutics is a clinical-stage pharmaceutical company focused on precision neuroscience and the development of transformational therapies for patients with neuropsychiatric and neurodevelopmental diseases. Its pipeline targets conditions with high unmet need, including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases. The company is advancing multiple programs through clinical development and is conducting an ongoing ENX-102 Phase 2 study in generalized anxiety disorder. Management states the Series B funding will propel advancement of the pipeline through multiple clinical stages and enable delivery of value-creating milestones. Engrail was incubated with support from Pivotal Life Sciences and aims to become a leader in neuroscience. Engrail Therapeutics is a neuroscience company that acquires, develops and commercializes patient-centric therapies, with lead compounds that are subtype-selective GABA-A modulators. The company is advancing a diverse pipeline, including lead assets ENX-101 and ENX-102 as well as internal preclinical programs. Earlier this year Engrail initiated a Phase 1b study for ENX-101 and a Phase 1a study for ENX-102. Engrail will use proceeds from its recent financing to accelerate clinical development and build out clinical development capabilities. The company operates via a flexible transaction model—licensing, co-development and company acquisitions—to acquire assets with validated mechanisms for nervous system diseases. Engrail was founded in 2019 and is supported by a long-term capital commitment from Nan Fung Life Sciences. Engrail Therapeutics focuses on acquiring, developing and commercializing therapies for diseases of the nervous system. Its lead pipeline asset is ENX-101, a subtype‑selective GABAA modulator that the company plans to advance clinically. Engrail applies a "science‑first" approach to identify compounds with validated mechanisms and a lower‑risk path to market. The company uses a flexible transaction model — including licensing, co‑development and company acquisitions — to build a diversified portfolio. Engrail closed a $32 million Series A to support ENX-101’s clinical development and is backed by a long‑term capital commitment from Nan Fung Life Sciences. Founded in 2019 and based in San Diego, Engrail emphasizes clinical strategy, regulatory planning, intellectual property and commercial positioning.

Participated · Series C · May 2021

Oculis is a helvetico-Icelandic biopharmaceutical company focused on creating innovative treatments for eye and neurological disorders. The firm is legally based in Zug with its operational headquarters in Lausanne. Its pipeline of ophthalmic therapies has attracted strong investor interest, reflected in two capital increases exceeding $100 million within a year. Management states that the newly secured funds will accelerate the clinical development of its drug candidates. The company positions itself as a leader in addressing unmet medical needs in ophthalmology through novel therapeutic approaches. Financially, Oculis has now raised at least $220 million across its last two rounds, underscoring sustained investor confidence. No revenue or user metrics were disclosed in the available article excerpt.

Participated · Series B · Mar 2021

Arctic Vision is a clinical-stage specialty ophthalmology company based in Shanghai and led by Founder and CEO Dr. Eddy Wu. The company focuses on developing therapies for pan-ocular diseases and holds a portfolio of three late-stage in-licensed products: ARVN001 for uveitic macular edema (UME), ARVN002 for pediatric progressive myopia, and ARVN003 for presbyopia. It completed an over US$100m Series B to advance its clinical programs. Proceeds will support clinical developments, registrational activities and commercialization efforts. The financing will also fund the establishment of in-house R&D capabilities, business development, and organizational growth.